Trodelvy Keytruda Combination Delivers Breakthr...

By João L. Carapinha

April 30, 2025

A Phase III trial (ASCENT-04/KEYNOTE-D19) has shown that the Trodelvy Keytruda combination improves progression-free survival over Keytruda plus chemotherapy in previously untreated PD-L1-positive metastatic triple-negative breast cancer (mTNBC). ...
AI Pediatric Sarcoma Diagnosis: Improving Speed and Accuracy in Cancer Classi...
Urgent Need for Pediatric Heart Devices
Journavx for Pain Management: Toward Affordability and Access
FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough i...
Advancing Pediatric Leukemia Trial: Precision Medicine and Transformative Res...
Reserve Antibiotics Benefits: G-BA Designates Meropenem/Vaborbactam as Critic...
NICE Grants Conditional Robotic Surgery Approval to Enhance Patient Care and ...
Neoadjuvant Immunotherapy Efficacy: Enhancing Treatment Strategies for Head a...
NICE Breakthrough: Record Positive Recommendations for Blood Cancer Treatment...
Approval of Pembrolizumab Enfortumab Therapy: Insights on Efficacy, Costs, an...
Engineering Resilience: Mastering Pharma Patent Expiration Strategy
Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefit...